Show simple item record

dc.contributor.authorZech, CJen_US
dc.contributor.authorBa-Ssalamah, Aen_US
dc.contributor.authorBerg, Ten_US
dc.contributor.authorChandarana, Hen_US
dc.contributor.authorChau, G-Yen_US
dc.contributor.authorGrazioli, Len_US
dc.contributor.authorKim, M-Jen_US
dc.contributor.authorLee, JMen_US
dc.contributor.authorMerkle, EMen_US
dc.contributor.authorMurakami, Ten_US
dc.contributor.authorRicke, Jen_US
dc.contributor.authorB Sirlin, Cen_US
dc.contributor.authorSong, Ben_US
dc.contributor.authorTaouli, Ben_US
dc.contributor.authorYoshimitsu, Ken_US
dc.contributor.authorKoh, D-Men_US
dc.date.accessioned2020-06-16T09:22:53Z
dc.date.issued2020-01en_US
dc.identifier.citationEuropean radiology, 2020, 30 (1), pp. 370 - 382en_US
dc.identifier.issn0938-7994en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3746
dc.identifier.eissn1432-1084en_US
dc.identifier.doi10.1007/s00330-019-06369-4en_US
dc.description.abstract<h4>Objectives</h4>The 8th International Forum for Liver Magnetic Resonance Imaging (MRI), held in Basel, Switzerland, in October 2017, brought together clinical and academic radiologists from around the world to discuss developments in and reach consensus on key issues in the field of gadoxetic acid-enhanced liver MRI since the previous Forum held in 2013.<h4>Methods</h4>Two main themes in liver MRI were considered in detail at the Forum: the use of gadoxetic acid for contrast-enhanced MRI in patients with liver cirrhosis and the technical performance of gadoxetic acid-enhanced liver MRI, both opportunities and challenges. This article summarises the expert presentations and the delegate voting on consensus statements discussed at the Forum.<h4>Results and conclusions</h4>It was concluded that gadoxetic acid-enhanced MRI has higher sensitivity for the diagnosis of hepatocellular carcinoma (HCC), when compared with multidetector CT, by utilising features of hyperenhancement in the arterial phase and hypointensity in the hepatobiliary phase (HBP). Recent HCC management guidelines recognise an increasing role for gadoxetic acid-enhanced MRI in early diagnosis and monitoring post-resection. Additional research is needed to define the role of HBP in predicting microvascular invasion, to better define washout during the transitional phase in gadoxetic acid-enhanced MRI for HCC diagnosis, and to reduce the artefacts encountered in the arterial phase. Technical developments are being directed to shortening the MRI protocol for reducing time and patient discomfort and toward utilising faster imaging and non-Cartesian free-breathing approaches that have the potential to improve multiphasic dynamic imaging.<h4>Key points</h4>• Gadoxetic acid-enhanced MRI provides higher diagnostic sensitivity than CT for diagnosing HCC. • Gadoxetic acid-enhanced MRI has roles in early-HCC diagnosis and monitoring post-resection response. • Faster imaging and free-breathing approaches have potential to improve multiphasic dynamic imaging.en_US
dc.formatPrint-Electronicen_US
dc.format.extent370 - 382en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectLiveren_US
dc.subjectHumansen_US
dc.subjectCarcinoma, Hepatocellularen_US
dc.subjectLiver Neoplasmsen_US
dc.subjectLiver Cirrhosisen_US
dc.subjectGadolinium DTPAen_US
dc.subjectContrast Mediaen_US
dc.subjectMagnetic Resonance Imagingen_US
dc.subjectArtifactsen_US
dc.subjectSwitzerlanden_US
dc.subjectFemaleen_US
dc.subjectMaleen_US
dc.subjectMultidetector Computed Tomographyen_US
dc.titleConsensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.en_US
dc.typeJournal Article
dcterms.dateAccepted2019-07-12en_US
rioxxterms.versionofrecord10.1007/s00330-019-06369-4en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2020-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEuropean radiologyen_US
pubs.issue1en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume30en_US
pubs.embargo.termsNo embargoen_US
dc.contributor.icrauthorKoh, Dow-Muen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/